论文部分内容阅读
目的评价坤泰胶囊与激素疗法(MHT)治疗围绝经期综合征的经济学基础。方法查找2000~2015年发表的有关坤泰胶囊和MHT治疗围绝经期综合征的随机对照试验(RCT)文献。按照Cochrane系统评价方法进行筛选,采用Revman 5.3软件进行Meta分析,研究两药的临床有效率、安全性和成本情况。结果 1坤泰胶囊治疗围绝经期综合征临床有效率高于激素(P<0.05);2坤泰胶囊治疗围绝经期综合征安全性优于激素(P<0.05);3临床有效率每升高1个百分点坤泰胶囊所需费用15.2元,激素所需费用12.5元。结论较激素而言,坤泰胶囊治疗围绝经期综合征有效率高、安全性好,临床可酌情运用。
Objective To evaluate the economic basis of Kuntai Capsule and Hormone Therapy (MHT) in treating perimenopausal syndrome. Methods Randomized controlled trials (RCTs) on kuntai capsules and MHT for peri-menopausal syndrome published from 2000 to 2015 were searched. According to the Cochrane systematic review method, Revman 5.3 software was used for meta-analysis to study the clinical efficacy, safety and cost of the two drugs. Results 1 Kuntai capsule treatment of perimenopausal syndrome clinical effective rate was higher than that of hormone (P <0.05); 2 Kuntai capsule treatment of perimenopausal syndrome better than hormone safety (P <0.05); 3 clinical effective rate per liter 1% higher Kuntai capsule costs 15.2 yuan, hormone costs 12.5 yuan. Conclusions Compared with hormones, Kuntai Capsule is effective and safe in the treatment of perimenopausal syndrome and can be used clinically in discretion.